Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
PaperCitations, authors & open-access status
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 259 citations, 2020 year and green oa status.
259
Citations
2020
Year
green
OA Status